Brind.
  1. Altria and Marlboro are diversifying products due to declining smoking rates, with the flagship Marlboro brand generating most revenue.

FDA granted Juul marketing approval for e-cigarettes, raising competitive pressure on Altria's nicotine alternatives portfolio.

4 reports, 4 independent Updated Aug 28
Gone quiet Reached 3 outlets in its first 24 hours
Reports
4
Developments
2
Repetition
75%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Well supportedReported by 4 independent outlets

FDA granted Juul marketing approval for e-cigarettes, raising competitive pressure on Altria's nicotine alternatives portfolio.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Altria is under investigation by the FDA regarding the misrepresentation of its product's regulatory status.Sub-event
  2. Juul's FDA approval intensifies competition for Altria, leading to NJOY sales halts.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped
  • winnipegfreepress.com
  • BarchartThe FDA Just Approved Juul’s E-Cigarettes. Does That Make Altria Stock a Buy Here? Following a prolonged and high-stakes legal battle, the U.S. Food and Drug Administration (FDA) granted Juul marketi
  • BenzingaThe Vaping Giant That Almost Died: JUUL's Shocking FDA Reversal In a significant reversal and a major boost for the embattled vaping company, the U.S. Food and Drug Administration (FDA) on Thursday a
  • GlobeNewswireCEA Industries Applauds FDA Authorization of JUUL Products, Signals Opportunity for U.S. Market Expansion Louisville, Colorado, July 18, 2025 (GLOBE NEWSWIRE) -- CEA Industries Inc. (NASDAQ: VAPE) (“